EP4028548A1 - Verfahren zur genotypisierung zur verarbeitung einer vielzahl von proben, insbesondere in fällen von hohem polymorphismus - Google Patents
Verfahren zur genotypisierung zur verarbeitung einer vielzahl von proben, insbesondere in fällen von hohem polymorphismusInfo
- Publication number
- EP4028548A1 EP4028548A1 EP20786024.8A EP20786024A EP4028548A1 EP 4028548 A1 EP4028548 A1 EP 4028548A1 EP 20786024 A EP20786024 A EP 20786024A EP 4028548 A1 EP4028548 A1 EP 4028548A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- sequence
- primers
- sequencing
- sequences
- universal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000003205 genotyping method Methods 0.000 title claims abstract description 21
- 238000012545 processing Methods 0.000 title description 3
- 238000000034 method Methods 0.000 claims abstract description 35
- 238000012163 sequencing technique Methods 0.000 claims description 61
- 238000003752 polymerase chain reaction Methods 0.000 claims description 30
- 230000000087 stabilizing effect Effects 0.000 claims description 30
- 238000007481 next generation sequencing Methods 0.000 claims description 26
- 239000002773 nucleotide Substances 0.000 claims description 19
- 125000003729 nucleotide group Chemical group 0.000 claims description 19
- 230000000692 anti-sense effect Effects 0.000 claims description 15
- 238000006243 chemical reaction Methods 0.000 claims description 13
- 239000011541 reaction mixture Substances 0.000 claims description 11
- 239000003381 stabilizer Substances 0.000 claims description 11
- 239000000203 mixture Substances 0.000 claims description 9
- 230000000295 complement effect Effects 0.000 claims description 6
- 230000004544 DNA amplification Effects 0.000 claims description 4
- 238000000151 deposition Methods 0.000 claims description 2
- 238000012165 high-throughput sequencing Methods 0.000 abstract description 6
- 238000012408 PCR amplification Methods 0.000 abstract description 2
- 230000003321 amplification Effects 0.000 description 18
- 238000003199 nucleic acid amplification method Methods 0.000 description 18
- 108020004414 DNA Proteins 0.000 description 9
- 238000005516 engineering process Methods 0.000 description 9
- 239000000523 sample Substances 0.000 description 8
- 108091093088 Amplicon Proteins 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- PCDQPRRSZKQHHS-XVFCMESISA-N CTP Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 PCDQPRRSZKQHHS-XVFCMESISA-N 0.000 description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Chemical class Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000012472 biological sample Substances 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000001226 triphosphate Substances 0.000 description 2
- 235000011178 triphosphate Nutrition 0.000 description 2
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- KBDWGFZSICOZSJ-UHFFFAOYSA-N 5-methyl-2,3-dihydro-1H-pyrimidin-4-one Chemical compound N1CNC=C(C1=O)C KBDWGFZSICOZSJ-UHFFFAOYSA-N 0.000 description 1
- PGSPUKDWUHBDKJ-UHFFFAOYSA-N 6,7-dihydro-3h-purin-2-amine Chemical compound C1NC(N)=NC2=C1NC=N2 PGSPUKDWUHBDKJ-UHFFFAOYSA-N 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 101100180399 Mus musculus Izumo1r gene Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 229960001456 adenosine triphosphate Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000008366 buffered solution Substances 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 230000000771 oncological effect Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000010008 shearing Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6832—Enhancement of hybridisation reaction
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/6858—Allele-specific amplification
Definitions
- low multiplexing conditions are understood to mean conditions making it possible to amplify a single target, or even 2, 3 or 4 targets simultaneously in the same reaction mixture.
- Sequencing is carried out using the pair of sequencing primers to amplify the sequences to be analyzed and the index reading primer to identify the patient to which the sequence relates.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR1910106A FR3100820A1 (fr) | 2019-09-12 | 2019-09-12 | Procédé de génotypage adapté au traitement d’un grand nombre d’échantillons, notamment en cas de polymorphisme élevé |
| PCT/FR2020/051568 WO2021048504A1 (fr) | 2019-09-12 | 2020-09-11 | Procédé de génotypage adapté au traitement d'un grand nombre d'échantillons, notamment en cas de polymorphisme élevé |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EP4028548A1 true EP4028548A1 (de) | 2022-07-20 |
Family
ID=69190887
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP20786024.8A Pending EP4028548A1 (de) | 2019-09-12 | 2020-09-11 | Verfahren zur genotypisierung zur verarbeitung einer vielzahl von proben, insbesondere in fällen von hohem polymorphismus |
Country Status (3)
| Country | Link |
|---|---|
| EP (1) | EP4028548A1 (de) |
| FR (1) | FR3100820A1 (de) |
| WO (1) | WO2021048504A1 (de) |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112012032586B1 (pt) | 2010-06-30 | 2021-08-17 | Bgi Genomics Co., Ltd | Métodos para determinar a sequência nucleotídica de um ácido nucléico de interesse e para determinar o genótipo hla em uma amostra |
| US10557134B2 (en) * | 2015-02-24 | 2020-02-11 | Trustees Of Boston University | Protection of barcodes during DNA amplification using molecular hairpins |
-
2019
- 2019-09-12 FR FR1910106A patent/FR3100820A1/fr active Pending
-
2020
- 2020-09-11 WO PCT/FR2020/051568 patent/WO2021048504A1/fr unknown
- 2020-09-11 EP EP20786024.8A patent/EP4028548A1/de active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| FR3100820A1 (fr) | 2021-03-19 |
| WO2021048504A1 (fr) | 2021-03-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN110719957B (zh) | 用于核酸靶向富集的方法和试剂盒 | |
| JP7389551B2 (ja) | Ｍｅｔエキソン１４欠失の検出と、関連する治療法 | |
| JP2022120043A (ja) | 単一方向デュアルプローブプライマー伸長による標的濃縮 | |
| WO2016181128A1 (en) | Methods, compositions, and kits for preparing sequencing library | |
| CN110392739B (zh) | 检测dna突变的测序方法 | |
| US20200318160A1 (en) | Sample to Sequence | |
| US11884981B2 (en) | Primer compositions for detecting thalassemia | |
| WO2019062614A1 (en) | METHOD FOR AMPLIFYING TARGET NUCLEIC ACID | |
| CN110564823B (zh) | 一种dna恒温扩增方法及试剂盒 | |
| US20220145380A1 (en) | Cost-effective detection of low frequency genetic variation | |
| EP4028548A1 (de) | Verfahren zur genotypisierung zur verarbeitung einer vielzahl von proben, insbesondere in fällen von hohem polymorphismus | |
| AU2006226873A1 (en) | Nucleic acid detection | |
| WO2021234269A1 (fr) | Procede de genotypage adapte au traitement simultane d'un grand nombre de patients | |
| EP4097254A1 (de) | Einfaches und schnelles hla-genotyping-verfahren | |
| FR2842534A1 (fr) | Amplification multiplex quantitative a l'echelle d'un genome, et applications a la detection de remaniements genomiques | |
| US20160083806A1 (en) | Sequence specific primer pool for multiplex pcr and method of detecting microbial infections in thalassemia patients | |
| Wijaya et al. | Nested PCR amplification secures DNA template quality and quantity in real-time mCOP-PCR screening for SMA | |
| EP1137804B1 (de) | Kennzeichnung einer substanz mittels eines reportergens und sequenzen, die für die in vitro expression des reportergens notwendig sind | |
| US20240132962A1 (en) | Genetic test kit for detecting thalassemia | |
| WO2023052735A1 (fr) | Méthode de détection de mutations rares sur biopsie liquide | |
| KR20240041142A (ko) | 타액, 혈액 및 정액 동시 검출을 위한 다중분석 역전사 중합효소 연쇄반응용 프라이머 세트 및 이를 포함하는 검출 키트 | |
| CN111394437A (zh) | 一种人类cyp2c19基因多态性的引物、探针、试剂盒及其应用 | |
| JP2003274975A (ja) | 遺伝子発現を検出する方法 | |
| FR2783000A1 (fr) | Procede d'amplification de la totalite des fragments d'adn d'un echantillon |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: UNKNOWN |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
| 17P | Request for examination filed |
Effective date: 20220322 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
| DAV | Request for validation of the european patent (deleted) | ||
| DAX | Request for extension of the european patent (deleted) | ||
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |